Content about Philadelphia

CARLISLE, Pa. — The Federal Trade Commission has approved Giant Food Stores' proposal to acquire 15 Genuardi's stores from Safeway.

The announcement follows Giant's Jan. 5 announcement that it would acquire the Genuardi's stores, all of which are located in the greater Philadelphia market. Giant also noted that under the terms of a consent order approved by the FTC, the Genuardi's located in Newtown, Pa., will be purchased by Newtown Market and will be operated as a McCaffrey's supermarket.

PHILADELPHIA — Downtown Philadelphia will be the site for Walgreens' next Well Experience flagship store, according to an online report published Friday by CBS/Philly. The new Walgreens will be located at Broad and Chestnut Streets in Center City, filling the space of what was once a Borders bookstore.

The retail space extends 26,000 sq. ft. across three floors.

The CBS/Philly report suggested the new store will open its doors this fall, citing the real estate agent who brokered the deal.

PHILADELPHIA — An integrated wellness team approach to diabetes care can help patients not only improve their condition, but also lower their prescription costs, according to new research presented at the American Association of Clinical Endocrinologists' 21st annual Scientific and Clinical Congress in Philadelphia.

PHILADELPHIA — The Coalition for Consumer Information on Cosmetics’ Leaping Bunny Program, the gold standard in cruelty-free certification of personal care and household products, is partnering with Drugstore.com's The Natural Store to increase awareness around cruelty-free shopping and the availability of cruelty-free products on the website.

MINNEAPOLIS — Supervalu on Monday announced three new executive appointments following the departure of Sue Klug, president of its Albertsons Southern California division.

Dan Sanders has been tapped to head Albertsons Southern California, Keith Wyche will lead Acme and Brian Audette has been named president at Cub Foods.

DEERFIELD, Ill. — Takeda Pharmaceutical will acquire privately owned drug maker URL Pharma for $800 million, the companies said Wednesday.

Takeda announced that it would acquire Philadelphia-based URL through a U.S. subsidiary for the upfront payment plus future milestone payments. Takeda said it expected the acquisition to contribute "significantly" to its sales and profits starting in fiscal year 2013.

PHILADELPHIA — Obesity adds more to healthcare costs than smoking does, according to a study published in the March Journal of Occupational and Environmental Medicine, the official publication of the American College of Occupational and Environmental Medicine.

PHILADELPHIA — Drug maker Shire will conduct two post-marketing trials to compare its treatment for attention deficit hyperactivity disorder with a competing drug, the company said Tuesday.

Shire announced that it would start two phase-4 trials comparing its drug, Vyvanse (lisdexamfetamine dimesylate), with Alza's Concerta (methylphenidate hydrochloride).

PHILADELPHIA — CVS Caremark's chief healthcare strategy officer on Friday outlined how the company's integrated offerings — retail pharmacy, pharmacy benefit management and retail clinics — are helping patients achieve better health by working to increase medication adherence and targeting behaviors to improve treatment for chronic diseases during a panel discussion at the Wharton Health Care Business Conference.

WOONSOCKET, R.I. — Recognizing that cardiovascular disease affects about 80 million people in the United States and is the No. 1 killer of Americans, CVS/pharmacy announced on Thursday that it is providing several free services, educational information and special product offers during February's American Heart Month.

PHILADELPHIA — The Food and Drug Administration has approved a drug made by Shire for attention deficit hyperactivity disorder, the company said Tuesday.

Shire announced the FDA approval of Vyvanse (lisdexamfetamine dimesylate) capsules as a maintenance treatment for adults with ADHD. The drug already was approved for use in children and was approved for treating ADHD in adults in 2008.

The company said the approval was based on a clinical trial that showed more ADHD patients controlling their symptoms with Vyvanse than with placebo.

PHILADELPHIA — The Food and Drug Administration has approved a generic drug for obesity made by Lannett, the drug maker said Tuesday.

Lannett announced the approval of phentermine hydrochloride capsules in the 15-mg strength.

Various versions of the drug had sales of $11 million at average wholesale price in 2011, according to Wolters Kluwer.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.